These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1123 related items for PubMed ID: 33882375

  • 1. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Zheng MM, Tu HY, Yang JJ, Zhang XC, Zhou Q, Xu CR, Jiang BY, Yang XN, Yang XR, Deng JY, Yang MY, Xu BF, Chen XM, Li YS, Wu YL.
    Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
    [Abstract] [Full Text] [Related]

  • 2. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
    Hendriks LEL, Bootsma G, Mourlanette J, Henon C, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Duchemann B, Cousin S, le Pechoux C, Botticella A, De Ruysscher D, Dingemans AC, Besse B.
    Eur J Cancer; 2019 Jul; 116():182-189. PubMed ID: 31203193
    [Abstract] [Full Text] [Related]

  • 3. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
    Chen XJ, Ren A, Zheng L, Zheng ED, Jiang T.
    Front Immunol; 2021 Jul; 12():651086. PubMed ID: 34248939
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Xu Q, Zhang X, Huang M, Dai X, Gao J, Li S, Sheng L, Huang K, Wang J, Liu L.
    Front Immunol; 2021 Jul; 12():731546. PubMed ID: 34484242
    [Abstract] [Full Text] [Related]

  • 6. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
    Bongiovanni A, Foca F, Menis J, Stucci SL, Artioli F, Guadalupi V, Forcignanò MR, Fantini M, Recine F, Mercatali L, Spadazzi C, Burgio MA, Fausti V, Miserocchi A, Ibrahim T.
    Front Immunol; 2021 Jul; 12():697298. PubMed ID: 34858389
    [Abstract] [Full Text] [Related]

  • 7. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, Hara N, Hotta K, Maeda Y, Kiura K.
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [Abstract] [Full Text] [Related]

  • 8. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
    Vergnenegre A, Geier M, Guisier F, Lamy R, Comet B, Le Garff G, Do P, Janicot H, Morel H, Decroisette C, Andre M, Falchero L, Paleiron N, Monnet I, GFPC Team.
    Cancer Med; 2020 Jan; 9(2):432-439. PubMed ID: 31747137
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I, Mezquita L, Rossoni C, Auclin E, Kossai M, Aboubakar F, Le Moulec S, Massé J, Masson M, Radosevic-Robin N, Alemany P, Rouanne M, Bluthgen V, Hendriks L, Caramella C, Gazzah A, Planchard D, Pignon JP, Besse B, Adam J.
    Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.
    Sheng J, Li H, Yu X, Yu S, Chen K, Pan G, Xie M, Li N, Zhou Z, Fan Y.
    Thorac Cancer; 2021 Nov; 12(22):3019-3031. PubMed ID: 34596346
    [Abstract] [Full Text] [Related]

  • 14. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X, Wang L, Chen S, Zhou F, Zhao J, Zhao W, Su C.
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [Abstract] [Full Text] [Related]

  • 15. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
    Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JG, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D'Argento E, Grossi F, Rijavec E, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Michele T, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficorella C, Porzio G, Pinato DJ.
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906
    [Abstract] [Full Text] [Related]

  • 16. Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India.
    Kumar S, Joga S, Biswas B, Dabkara D, Prasad KT, Singh N, Malik PS, Khurana S, Ganguly S, Muthu V, Batra U.
    Curr Probl Cancer; 2020 Jun; 44(3):100549. PubMed ID: 32035693
    [Abstract] [Full Text] [Related]

  • 17. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
    Ardizzoni A, Azevedo S, Rubio-Viqueira B, Rodríguez-Abreu D, Alatorre-Alexander J, Smit HJM, Yu J, Syrigos K, Trunzer K, Patel H, Tolson J, Cardona A, Perez-Moreno PD, Newsom-Davis T.
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737339
    [Abstract] [Full Text] [Related]

  • 18. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
    Lang D, Huemer F, Rinnerthaler G, Horner A, Wass R, Brehm E, Akbari K, Granitz M, Hutarew G, Kaiser B, Greil R, Lamprecht B.
    Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80 years or older.
    Saito Z, Fujita K, Okamura M, Ito T, Yamamoto Y, Kanai O, Hashimoto M, Nakatani K, Sawai S, Mio T.
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1405. PubMed ID: 33934572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.